Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

S. Banerjee; M. Imbimbo; P. Roxburgh; J-W. Kim; M.H. Kim; R. Plummer; S. Stemmer; B. You; M. Ferguson; R.T. Penson; D. O'Malley; K. Meyer; H. Gao; H. Angell; A. Tablante Nunes; S. Domchek; Y. Drew

doi:10.1016/j.annonc.2022.07.657

YUHSpace

BROWSE

0 158

Cited 0 times in

Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Authors: S. Banerjee ; M. Imbimbo ; P. Roxburgh ; J-W. Kim ; M.H. Kim ; R. Plummer ; S. Stemmer ; B. You ; M. Ferguson ; R.T. Penson ; D. O'Malley ; K. Meyer ; H. Gao ; H. Angell ; A. Tablante Nunes ; S. Domchek ; Y. Drew